Bionano Genomics Inc

NASDAQ:BNGOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Oct 31, 2024

Show headlines and story abstract

• Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules, from 4:30PM ET on Thursday Oct 31, 2024 by Dow Jones

  4:30PM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: BNGO
  
  Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
  
  SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the "Warrants") at a combined offering price of $0.3039 per share of common stock and accompanying Warrants. The Warrants have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the "Stockholder Approval"). The Series C warrants expire five years following the date of the Stockholder Approval and the short-term Series D warrants expire eighteen months following the date of Stockholder Approval.
  

• Press Release: Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules, from 4:30PM ET on Thursday Oct 31, 2024 by Dow Jones

  4:30PM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: BNGO
  
  Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
  
  SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the "Warrants") at a combined offering price of $0.3039 per share of common stock and accompanying Warrants. The Warrants have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the "Stockholder Approval"). The Series C warrants expire five years following the date of the Stockholder Approval and the short-term Series D warrants expire eighteen months following the date of Stockholder Approval.
  

• Bionano Genomics Offers $3 Million of Shares, Warrants, from 12:19PM ET on Thursday Oct 31, 2024 by MT Newswires

  12:19PM ET on Thursday Oct 31, 2024 by MT Newswires
  Companies Mentioned: BNGO
  12:19 PM EDT, 10/31/2024 (MT Newswires) -- Bionano Genomics (BNGO) said Thursday it is offering 9.88 million common shares and series C and series D warrants, each to purchase additional 9.88 million shares, in a registered direct offering for $3 mi...

• Bionano Adjourns Special Meeting of Stockholders to November 27, 2024, from 8:10AM ET on Thursday Oct 31, 2024 by Dow Jones

  8:10AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: BNGO
  
  Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
  
  Special Meeting of Stockholders Adjourned Due to Lack of Quorum
  
  SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the "Special Meeting") because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately 30.7% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting. Based on the preliminary reports from the votes submitted as of October 30, 2024, approximately 76.3% of votes represented in person or by proxy at the Special Meeting were voted "For" the proposal.